Pérdida de Peso

NNMT Inhibitor | Longevity & Metabolic Enhancement

5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular NAD+ levels and mitochondrial function.

Prohibitin-Targeting Peptidomimetic | Experimental Anti-Obesity

Chimeric adipose-vasculature-targeted peptidomimetic targeting prohibitin/annexin A2 on white adipose tissue endothelium, delivering pro-apoptotic D-(KLAKLAK)2 motif.

Modified hGH Fragment | Fat Loss Peptide

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the side effects of full growth hormone.

Mitochondrial Uncoupler | Metabolic Enhancer

BAM-15 is a synthetic mitochondrial uncoupler that has emerged as a promising research compound for obesity and metabolic disorders.

Long-Acting Amylin Receptor Agonist | Weight Loss & Diabetes

Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes.

Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release

Modified growth hormone releasing hormone engineered for extended duration via albumin-binding technology. DAC binds to albumin, extending half-life and providing continuous GHRH receptor stimulation.

GHRH/GHRP Combination | Growth Hormone Optimization

A dual-pathway protocol combining CJC-1295 and Ipamorelin that targets growth hormone secretion through complementary mechanisms.

Human Growth Hormone | Somatropin

Human Growth Hormone (HGH/Somatropin) is a 191-amino acid polypeptide hormone FDA-approved for pediatric and adult growth hormone deficiency, HIV-associated wasting, and other conditions.

Growth Hormone Fragment | Fat Loss Peptide

HGH Fragment 176-191 is the fat-burning segment of human growth hormone, corresponding to amino acids 176 through 191 of the full GH molecule.

Four-Peptide Regenerative Blend

KLOW builds upon GLOW protocol by adding KPV for enhanced anti-inflammatory action.

Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes

First-in-class dual GLP-1 and glucagon receptor agonist combining appetite suppression with thermogenesis stimulation.

Ghrelin Receptor Agonist | Oral Growth Hormone Secretagogue

Oral compound activating ghrelin receptors to trigger growth hormone release while preserving natural production.

Péptido derivado de mitocondrias estudiado para metabolismo

MOTS-c es un péptido derivado de mitocondrias codificado dentro del ADN mitocondrial, estudiado en modelos animales por su papel en la regulación metabólica, sensibilidad a la insulina y adaptaciones similares al ejercicio.

Oral Small-Molecule GLP-1 Receptor Agonist | Weight Loss & Diabetes

First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction

Triple GLP-1/GIP/Glucagon Agonist | Weight Loss & Diabetes

Novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase II trials demonstrated 24.2% weight loss at 48 weeks—the highest recorded for obesity medications.

Agonista del receptor GLP-1 aprobado por la FDA

Semaglutide es un agonista del receptor GLP-1 aprobado por la FDA para diabetes tipo 2 y control crónico del peso, diseñado con acilación de ácidos grasos para una vida media de una vez por semana.

Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes

Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy.

Análogo de GHRH estabilizado aprobado por la FDA

Tesamorelin es un análogo de GHRH estabilizado y el único secretagogo de hormona del crecimiento con aprobación de la FDA específicamente para reducir el exceso de grasa visceral (en lipodistrofia asociada al VIH).

Agonista dual del receptor GIP/GLP-1 aprobado por la FDA

Tirzepatida es un agonista dual aprobado por la FDA de receptores GIP y GLP-1 para diabetes tipo 2 y control del peso, produciendo mayor reducción promedio de peso que los agentes solo GLP-1 en ensayos.